Cardiology

Top Story

Sacubitril–valsartan cost-effective for patients with heart failure

August 29, 2016

Sacubitril–valsartan therapy offers a reasonable value for patients with chronic heart failure to reduce cardiovascular mortality and morbidity, according to recent research.

Alexander T. Sandhu, MD, MS, of Stanford University Center for Primary Care and Outcomes Research, and colleagues used a Markov decision model to assess the cost-effectiveness of sacubitril–valsartan vs. lisinopril.

In the Journals

SAVE: CPAP does not reduce CV events in patients with CVD, sleep apnea

August 29, 2016
In patients with CVD and moderate-to-severe obstructive sleep apnea, treatment with continuous positive airway pressure plus the usual care did not reduce CV events…
In the Journals

Majority of clinicians overestimate harms, benefits of treatment

August 29, 2016
Most resident and attending internal medicine physicians overestimated both the benefits and harms of common medical tests and treatments, according to findings…
In the Journals

Revascularization for intermittent leg claudication improves patient-reported outcomes

August 29, 2016
Patient-reported outcomes including walking function, health-related quality of life and symptoms were significantly higher among patients with intermittent leg…
Meeting News CoveragePerspective

OPTICARE: Enhanced cardiac rehabilitation program improves quality of life, but not CV risk score

August 29, 2016
Patients recovering from MI who participated in enhanced cardiac rehabilitation programs for at least 1 year showed an improved quality of life compared with those in a…
More News Headlines »
morganatic-roan